Market Cap 41.98M
Revenue (ttm) 3.50M
Net Income (ttm) -5.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -166.00%
Debt to Equity Ratio 0.00
Volume 102,300
Avg Vol 138,550
Day's Range N/A - N/A
Shares Out 36.19M
Stochastic %K 46%
Beta 1.00
Analysts Strong Sell
Price Target $7.00

Company Profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products f...

Industry: Biotechnology
Sector: Healthcare
Phone: 561 743 8333
Fax: 561 743 8343
Address:
1044 North U.S. Highway One, Suite 201, Jupiter, United States
Tarrytabby
Tarrytabby Oct. 1 at 6:07 PM
$DYAI I could imagine that speculative funds/investors are stocking up here at the beginning of the quarter or there will be news.
0 · Reply
Jbaffs
Jbaffs Oct. 1 at 3:36 PM
$DYAI After tomorrows close they will have been above $1 for ten days in a row which removes the delisting risk.
1 · Reply
Jbaffs
Jbaffs Sep. 29 at 3:12 PM
$DYAI the worst stock board ever
2 · Reply
Glopolon
Glopolon Sep. 23 at 3:11 PM
$DYAI $5 target from Hallum https://m.uk.investing.com/news/analyst-ratings/craighallum-initiates-dyadic-international-stock-with-buy-rating-93CH-4254630?ampMode=1#origin=https%3A%2F%2Fwww.google.com%2F&cap=swipe,education&webview=1&dialog=1&viewport=natural&visibilityState=prerender&prerenderSize=1&viewerUrl=https%3A%2F%2Fwww.google.com%2Famp%2Fs%2Fm-uk-investing-com.cdn.ampproject.org%2Fc%2Fs%2Fm.uk.investing.com%2Fnews%2Fanalyst-ratings%2Fcraighallum-initiates-dyadic-international-stock-with-buy-rating-93CH-4254630%3FampMode=1&usqp=mq331AQIUAKwASCAAgM%25253D&amp_kit=1
0 · Reply
Glopolon
Glopolon Sep. 22 at 10:19 PM
$DYAI From Aug 1, 2005, re: Fermbox Bio https://www.cbs42.com/business/press-releases/ein-presswire/836232491/biotech-in-focus-indias-biomanufacturing-momentum-and-fermbox-bios-role-in-precision-fermentation/
0 · Reply
Glopolon
Glopolon Sep. 21 at 11:41 PM
$DYAI The ability of a protein production platform to make human like glycans opens the door to monoclonal antibody production.
0 · Reply
Glopolon
Glopolon Sep. 21 at 11:39 PM
$DYAI One of the more important advances to the C1 platform since the Dupont deal was the creation of a line that can produce human-like glycan structures. https://dyadic.com/dyadic-announces-achieving-human-like-glycan-structures-from-its-engineered-c1-cell-line/
0 · Reply
Glopolon
Glopolon Sep. 21 at 8:08 PM
$DYAI The industrial production rights have since ended, as well.. So that is opening up that arena again.
0 · Reply
Glopolon
Glopolon Sep. 21 at 8:07 PM
$DYAI It is not accurate to say they are pre-revenue. They sold their industrial production rights to Dupont for $70M in 2015, and prior to that, they were getting revenue from their protein production platform. They have refined the C1 platform since then, and they do not have a lot of R&D spend.
0 · Reply
StockHounding
StockHounding Sep. 21 at 4:03 PM
$CERS woke up Friday. Impressive flag $ULY is starting to climb with $AMZE Watch for continuation Ticker 🔥PAVS high watch tomorrow. Zero borrow and ready to run. $NCL someone or something is buying $DYAI bullish
0 · Reply
Latest News on DYAI
Dyadic to Present at Investor Conferences and BPI East

Sep 4, 2025, 9:00 AM EDT - 4 weeks ago

Dyadic to Present at Investor Conferences and BPI East


Dyadic International, Inc. (DYAI) Q1 2025 Earnings Call Transcript

May 14, 2025, 11:31 PM EDT - 5 months ago

Dyadic International, Inc. (DYAI) Q1 2025 Earnings Call Transcript


Dyadic to Present at World Vaccine Congress | Washington

Apr 16, 2025, 2:00 PM EDT - 6 months ago

Dyadic to Present at World Vaccine Congress | Washington


Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 10:58 PM EDT - 6 months ago

Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript


Dyadic to Attend Multiple Industry Events in March

Mar 6, 2025, 8:30 AM EST - 7 months ago

Dyadic to Attend Multiple Industry Events in March


Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript

Nov 16, 2024, 8:16 PM EST - 11 months ago

Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript


Dyadic to Attend Industry Events in June

May 30, 2024, 4:30 PM EDT - 1 year ago

Dyadic to Attend Industry Events in June


Dyadic to Attend Industry and Investor Events in May

May 8, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Industry and Investor Events in May


Dyadic to Attend Industry Events in April

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Industry Events in April


Dyadic to Attend Industry Events in March

Mar 1, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend Industry Events in March


Dyadic Attends Investor Events in December

Nov 30, 2023, 8:30 AM EST - 2 years ago

Dyadic Attends Investor Events in December


Tarrytabby
Tarrytabby Oct. 1 at 6:07 PM
$DYAI I could imagine that speculative funds/investors are stocking up here at the beginning of the quarter or there will be news.
0 · Reply
Jbaffs
Jbaffs Oct. 1 at 3:36 PM
$DYAI After tomorrows close they will have been above $1 for ten days in a row which removes the delisting risk.
1 · Reply
Jbaffs
Jbaffs Sep. 29 at 3:12 PM
$DYAI the worst stock board ever
2 · Reply
Glopolon
Glopolon Sep. 23 at 3:11 PM
$DYAI $5 target from Hallum https://m.uk.investing.com/news/analyst-ratings/craighallum-initiates-dyadic-international-stock-with-buy-rating-93CH-4254630?ampMode=1#origin=https%3A%2F%2Fwww.google.com%2F&cap=swipe,education&webview=1&dialog=1&viewport=natural&visibilityState=prerender&prerenderSize=1&viewerUrl=https%3A%2F%2Fwww.google.com%2Famp%2Fs%2Fm-uk-investing-com.cdn.ampproject.org%2Fc%2Fs%2Fm.uk.investing.com%2Fnews%2Fanalyst-ratings%2Fcraighallum-initiates-dyadic-international-stock-with-buy-rating-93CH-4254630%3FampMode=1&usqp=mq331AQIUAKwASCAAgM%25253D&amp_kit=1
0 · Reply
Glopolon
Glopolon Sep. 22 at 10:19 PM
$DYAI From Aug 1, 2005, re: Fermbox Bio https://www.cbs42.com/business/press-releases/ein-presswire/836232491/biotech-in-focus-indias-biomanufacturing-momentum-and-fermbox-bios-role-in-precision-fermentation/
0 · Reply
Glopolon
Glopolon Sep. 21 at 11:41 PM
$DYAI The ability of a protein production platform to make human like glycans opens the door to monoclonal antibody production.
0 · Reply
Glopolon
Glopolon Sep. 21 at 11:39 PM
$DYAI One of the more important advances to the C1 platform since the Dupont deal was the creation of a line that can produce human-like glycan structures. https://dyadic.com/dyadic-announces-achieving-human-like-glycan-structures-from-its-engineered-c1-cell-line/
0 · Reply
Glopolon
Glopolon Sep. 21 at 8:08 PM
$DYAI The industrial production rights have since ended, as well.. So that is opening up that arena again.
0 · Reply
Glopolon
Glopolon Sep. 21 at 8:07 PM
$DYAI It is not accurate to say they are pre-revenue. They sold their industrial production rights to Dupont for $70M in 2015, and prior to that, they were getting revenue from their protein production platform. They have refined the C1 platform since then, and they do not have a lot of R&D spend.
0 · Reply
StockHounding
StockHounding Sep. 21 at 4:03 PM
$CERS woke up Friday. Impressive flag $ULY is starting to climb with $AMZE Watch for continuation Ticker 🔥PAVS high watch tomorrow. Zero borrow and ready to run. $NCL someone or something is buying $DYAI bullish
0 · Reply
JimCruz600
JimCruz600 Sep. 21 at 10:00 AM
$DYAI Biotech with novel approach. Pre-revenue volatility. Chart shows high risk/reward. Avoid.
0 · Reply
Sidoti
Sidoti Sep. 18 at 2:20 PM
Dyadic Applied BioSolutions ($DYAI) Management Team presented today at the Sidoti Small-Cap Virtual Conference. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_JBNfmFr4SEWg1a1HO2Bhdw
0 · Reply
Pipelinepivots
Pipelinepivots Sep. 14 at 4:45 AM
For MITQ The golden cross is here. MITQ is loaded ✔️ Micro float ✔️ Clean chart ✔️ Zero crowd This is a breakout waiting for a spark and when it hits, it won’t walk, it’ll gap. $EYEN $RNAZ $REVB $DYAI $ARAV
1 · Reply
Glopolon
Glopolon Sep. 10 at 3:32 PM
$DYAI https://seekingalpha.com/pr/20221353-dyadic-to-present-at-investor-conferences-and-bpi-east Link to the morning webcast is in the PR. Nice overview. Things heading in the right direction here.
1 · Reply
Jbaffs
Jbaffs Sep. 5 at 1:57 PM
$CHRS $OMER I've only done this once before because there is absolutely nothing gained by doing it, only blow back. I own stock in $DYAI, an extremely small cap stock that has the potential to explode their sales. They have a technology that beats current competition, produced at 1/20th the cost and 400% throughput. Very risky, but if they execute, stock will explode from these levels. Do your own research, not stock advice. Great article out recently that encapsulates what they're doing.
4 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 9:12 AM
$DYAI Great piece that accurately captures DYAI's current position. So if you want to refresh your understanding of DYAI or learn about DYAI for the first time, this is essential reading. https://beyondspx.com/quote/DYAI/dyadic-s-precision-pivot-applied-biosolutions-driving-towards-profitability-nasdaq-dyai#analysis
0 · Reply
Jbaffs
Jbaffs Sep. 2 at 6:27 PM
$DYAI https://beyondspx.com/quote/DYAI/dyai-s-dual-platform-strategy-commercializing-proteins-for-near-term-growth-nasdaq-dyai#analysis
0 · Reply
Glopolon
Glopolon Aug. 24 at 5:35 PM
$DYAI https://www.youtube.com/watch?v=VWVN80XiPqs&t=2s
0 · Reply
FintechInvestmentGroup
FintechInvestmentGroup Aug. 23 at 11:29 AM
$DYAI Dyadic International Inc is facing biopharmaceutical technology adoption challenges
1 · Reply
ZacksSCR
ZacksSCR Aug. 15 at 1:33 PM
$DYAI: One Strain To Rule Them All https://buff.ly/mg6iFag
0 · Reply
d_risk
d_risk Aug. 14 at 3:26 AM
$DYAI - DYADIC INTERNATIONAL INC - 10Q - Updated Risk Factors DYAI warns that failure to meet Nasdaq listing requirements could lead to delisting, pushing its stock to over-the-counter markets with no guarantee of eligibility or liquidity. #Biotechnology #DelistingRisk #MarketLiquidity #NasdaqCompliance #StockListingRisk 🟢 Added 🟠 Removed https://d-risk.ai/DYAI/10-Q/2025-08-13
1 · Reply
Glopolon
Glopolon Aug. 13 at 9:45 PM
$DYAI Joe H. anticipating cash generation by end of 2026. Cash spend should be equal or less in 2026.
1 · Reply